Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687969 · ClinicalTrials.gov registry record
Multimodal Machine Learning Characterization of Solid Tumors
A clinical trial of Prostate Cancer and Glioma, sponsored by Ciprian Catana, MD, PhD.
- Active
- Registry status
- 135
- Enrollment target
- 2
- Study locations
NCT04687969 is a study of Prostate Cancer and Glioma that is active but no longer recruiting, run by Ciprian Catana, MD, PhD. The registered enrollment target is 135 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04687969, a study of Prostate Cancer and Glioma, is active but no longer recruiting, sponsored by Ciprian Catana, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Conditions Studied
Interventions
- DRUG [18F]DCFPyL
- RADIATION PET/MRI scanner
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2022-10-23 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04687969
The ClinicalTrials.gov registry entry for NCT04687969 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Ciprian Catana, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which [18F]DCFPyL is the first listed.
NCT04687969 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04687969 about?
NCT04687969 is a clinical study titled "Multimodal Machine Learning Characterization of Solid Tumors". This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
What is the current status of trial NCT04687969?
This trial is currently active not recruiting. The enrollment target is 135 participants. The study started on 2022-10-23. Estimated completion is 2025-12-31.
What conditions does trial NCT04687969 study?
This clinical trial studies the following conditions: Prostate Cancer, Glioma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Radical Prostatectomy.
What interventions are being tested in trial NCT04687969?
The interventions under investigation include: [18F]DCFPyL (DRUG), PET/MRI scanner (RADIATION).
Who is sponsoring clinical trial NCT04687969?
This trial is sponsored by Ciprian Catana, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04687969 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.